Royal Surrey Hospital NHS Foundation Trust, Guildford, UK.
Department of Peri-Operative Medicine (Critical Care), St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Anaesthesia. 2023 Jul;78(7):874-883. doi: 10.1111/anae.15955. Epub 2023 Jan 19.
There are a diverse range of haematological malignancies with varying clinical presentations and prognoses. Patients with haematological malignancy may require admission to critical care at the time of diagnosis or due to treatment related effects and complications. Although the prognosis for such patients requiring critical care has improved, there remain uncertainties in optimal clinical management. Identification of patients who will benefit from critical care admission is challenging and selective involvement of palliative care may help to reduce unnecessary and non-beneficial treatments. While patients with haematological malignancy can present a challenge to critical care physicians, good outcomes can be achieved. In this narrative review, we provide a brief overview of relevant haematological malignancies for the critical care physician and a summary of recent treatment advances. Subsequently, we focus on critical care management for the patient with haematological malignancy including sepsis; acute respiratory failure; prevention and treatment of tumour lysis syndrome; thrombocytopaenia; and venous thromboembolism. We also discuss immunotherapeutic-specific related complications and their management, including cytokine release syndrome and immune effector cell associated neurotoxicity syndrome associated with chimeric antigen receptor T-cell therapy. While the management of haematological malignancies is highly specialised and increasingly centralised, acutely unwell patients often present to their local hospital with complications requiring critical care expertise. The aim of this review is to provide a contemporary overview of disease and management principles for non-specialist critical care teams.
血液系统恶性肿瘤种类繁多,临床表现和预后各异。血液系统恶性肿瘤患者在诊断时或因治疗相关的影响和并发症而可能需要入住重症监护病房。尽管需要重症监护的此类患者的预后有所改善,但最佳临床管理仍存在不确定性。确定需要重症监护入院的患者具有挑战性,姑息治疗的选择性参与可能有助于减少不必要和无益的治疗。虽然血液系统恶性肿瘤患者可能对重症监护医生构成挑战,但可以取得良好的结果。在本叙述性综述中,我们简要概述了重症监护医生相关的血液系统恶性肿瘤,并总结了最近的治疗进展。随后,我们重点介绍了血液系统恶性肿瘤患者的重症监护管理,包括脓毒症;急性呼吸衰竭;肿瘤溶解综合征的预防和治疗;血小板减少症;和静脉血栓栓塞症。我们还讨论了免疫治疗相关的特定并发症及其管理,包括嵌合抗原受体 T 细胞治疗相关的细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。虽然血液系统恶性肿瘤的管理高度专业化且日益集中化,但病情急性恶化的患者通常会因并发症而在当地医院就诊,需要重症监护专业知识。本综述的目的是为非专业重症监护团队提供疾病和管理原则的现代概述。